ライフサイエンスコーパス: Chagas

1 Chagas cardiomyopathy was associated (P<0.01) with male

2 Chagas disease (CD) affects over 300 000 people in the U

3 Chagas disease (CD) in the United States is severely und

4 Chagas disease affects an estimated 300,000 individuals

5 Chagas disease caused by Trypanosoma cruzi is a paradigm

6 Chagas disease causes a severe inflammatory dilated chro

7 Chagas disease is a chronic infection caused by Trypanos

8 Chagas disease is a chronic infection in humans caused b

9 Chagas disease is a deadly infection caused by the proto

10 Chagas disease is a major public health issue, affecting

11 Chagas disease is a neglected tropical disease caused by

12 Chagas disease is a neglected tropical disease with 6-7

13 Chagas disease is a well-known cause of cardiomyopathy i

14 Chagas disease is amongst the ten most important neglect

15 Chagas disease is an important disease affecting million

16 Chagas disease is caused by the intracellular protozoan

17 Chagas disease is caused by the parasite Trypanosoma cru

18 Chagas disease is caused by the protozoan parasite Trypa

19 Chagas disease is caused by the protozoan parasite Trypa

20 Chagas disease is caused by the protozoan parasite Trypa

21 Chagas disease is caused by the protozoan Trypanosoma cr

22 Chagas disease is characterised by an acute phase, which

23 Chagas disease is considered the most important parasiti

24 Chagas disease is currently prevalent in European countr

25 Chagas disease is endemic in Latin America and an emergi

26 Chagas disease is now an active disease in the urban cen

27 Chagas disease is one of the main public health issues i

28 Chagas disease was diagnosed in 25 (19%) patients.

29 Chagas disease, caused by infection with the protozoan p

30 Chagas disease, caused by the eukaryotic (protozoan) par

31 Chagas disease, caused by the intracellular protozoan pa

32 Chagas disease, caused by the parasite Trypanosoma cruzi

33 Chagas disease, caused by the parasite Trypanosoma cruzi

34 Chagas disease, caused by the protozoan parasite Trypano

35 Chagas disease, caused by the protozoan parasite Trypano

36 Chagas disease, caused by the protozoan Trypanosoma cruz

37 Chagas disease, caused by Trypanosoma cruzi parasite, wa

38 Chagas disease, caused by Trypanosoma cruzi, is a major

39 Chagas disease, caused by Trypanosoma cruzi, is an impor

40 Chagas disease, leishmaniasis and sleeping sickness affe

41 Chagas disease, which was once thought to be confined to

42 Chagas disease-associated cardiomyopathy is clinically s

43 Chagas drug discovery has been hampered by a lack of val

44 Chagas heart disease is an inflammatory cardiomyopathy t

45 Chagas' disease is an important cause of cardiomyopathy

46 Chagas' disease, caused by the protozoan parasite Trypan

47 nding peptide motifs were identified from 28 Chagas repertoires using a bacterial display random 12-m

48 In a blinded validation set (n = 72), 30/30 Chagas were positive, 30/30 non-Chagas were negative, an

49 >100 years ago, much has been learned about Chagas disease pathogenesis; however, the outcome of T.

50 In Venezuela, active Chagas disease transmission has been reported, with sero

51 ritic cell-based immunotherapeutic for acute Chagas disease in an attempt to delay or prevent the car

52 peutic strategies for the treatment of acute Chagas disease are feasible and that this approach may w

53 ty on parasitemia in a murine model of acute Chagas disease.

54 Prospective observational study where adult Chagas disease patients accepting to receive benznidazol

55 hylase (CYP51) were proven effective against Chagas, and antifungal drugs posaconazole and ravuconazo

56 oximately 8 million people in Latin America, Chagas disease is now becoming a serious global health p

57 gnoses included schistosomiasis (Africa) and Chagas disease (Americas).

58 ogenesis of dilated cardiomyopathy (DCM) and Chagas heart disease.

59 emic hypertension (SH), rheumatic fever, and Chagas' disease (C'D) are higher in LA.

60 m of human African trypanosomiasis (HAT) and Chagas disease.

61 Leishmaniasis and Chagas disease are endemic in many countries, and re-eme

62 fection, schistosomiasis, leishmaniasis, and Chagas disease, is being led by nonprofit product develo

63 panosomes are causative agents of Nagana and Chagas disease respectively, and speciated about 300 mil

64 hypertensive heart disease, nonischemic and Chagas cardiomyopathies, rheumatic heart disease, and co

65 nsible for human African trypanosomiasis and Chagas disease.

66 line HAT (Human African Trypanosomiasis) and Chagas chemical boxes, two collections grouping 404 non-

67 es for developing an easy to synthesize anti-Chagas agent.

68 As Chagas disease continues to expand beyond tropical and s

69 es responsible for such human pathologies as Chagas disease, sleeping sickness, and leishmaniasis.

70 rase chain reaction (RT-PCR) in asymptomatic Chagas carriers.

71 ole treatment, of patients with asymptomatic Chagas disease showed a significant reduction in antigen

72 In Latin America, cardiomyopathy caused by Chagas disease is endemic.

73 HF) with reduced ejection fraction caused by Chagas' disease, with other etiologies, in the era of mo

74 motifs were selected and mapped to candidate Chagas antigens.

75 Our results demonstrated that cardiac Chagas patients have a lower intensity of expression of

76 ory process that can lead to cardiomyopathy (Chagas disease).

77 Since the discovery of T. cruzi by Carlos Chagas >100 years ago, much has been learned about Chaga

78 intracellular protozoan parasite that causes Chagas disease as a zoonotic pathogen.

79 Trypanosoma cruzi, the parasite that causes Chagas disease, the elongated, flagellated trypomastigot

80 of genomic DNA from the parasite that causes Chagas disease, Trypanosoma cruzi, directly in whole, un

81 Trypanosoma cruzi, the parasite that causes Chagas disease.

82 ma cruzi, the protozoan parasite that causes Chagas' disease, a potential life-threatening illness en

83 rs for Disease Control and Prevention (CDC), Chagas disease (CD) may affect 1.31% of Latin American i

84 Chronic Chagas disease cardiomyopathy, caused by Trypanosoma cru

85 vidence of its effectiveness against chronic Chagas disease.

86 ical aspects of the disease, such as chronic Chagas disease without detectable cardiac pathology, as

87 OS] in the Treatment of Asymptomatic Chronic Chagas Disease [P05267] [STOP CHAGAS]: NCT01377480).

88 cardiac, digestive and asymptomatic) chronic Chagas disease manifestations.

89 0% of infected patients will develop chronic Chagas cardiomyopathy (CCC), an inflammatory cardiomyopa

90 in the pathogenesis of experimental chronic Chagas disease, favoring inflammation and fibrogenesis.

91 nt and severe manifestation of human chronic Chagas disease and is characterized by heart failure, ve

92 In chronic Chagas disease, RV systolic dysfunction is more commonly

93 gainst PBMC samples from a cohort of chronic Chagas' disease patients, using IFN-gamma secretion as a

94 he clinical onset and progression of chronic Chagas' disease.

95 Chagas disease occur annually due to chronic Chagas disease cardiomyopathy (CCC), an inflammatory car

96 study included 158 individuals with chronic Chagas disease who underwent cardiac magnetic resonance.

97 kg/day for 60 days in 30 adults with chronic Chagas disease.

98 dysfunction (LVSD) in patients with chronic Chagas heart disease, while the val/val genotype was ass

99 ypanosomal activity in patients with chronic Chagas' disease.

100 suicide, liver cancer, diabetes, cirrhosis, Chagas disease, African trypanosomiasis, melanoma, and o

101 s both sensitive and specific for congenital Chagas disease diagnosis.

102 pecific diagnostic techniques for congenital Chagas disease may help improve regional initiatives to

103 age with benznidazole to prevent congenital Chagas disease (CCD), as well as the usefulness of polym

104 omen of childbearing age prevents congenital Chagas disease.

105 since the 1990s, but symptomatic congenital Chagas disease still represents a significant, albeit ch

106 number of infants diagnosed with congenital Chagas disease, many infants remain undiagnosed.

107 nfants (4.9%) were diagnosed with congenital Chagas disease.

108 s against other protozoal species: T. cruzi (Chagas disease), Leishmania major (cutaneous leishmanias

109 cruzi seropositives, 120 (24%) had definite Chagas cardiomyopathy, and among 488 T cruzi seronegativ

110 ytotoxicity could play a role in determining Chagas disease progression.

111 te the possibility of using RDTs to diagnose Chagas disease, thereby decreasing the time to treatment

112 Each Chagas disease group displayed distinct gene expression

113 nocidal therapy in patients with established Chagas' cardiomyopathy is unproven.

114 th benznidazole in patients with established Chagas' cardiomyopathy significantly reduced serum paras

115 e Instituto Nacional de Infectologia Evandro Chagas database who were enrolled between Jan 1, 2000, a

116 cellular experiments, cures the experimental Chagas disease with 100% efficacy, and suppresses viscer

117 For Chagas disease, a more extensive validation of the test

118 opes, and applied it to develop an assay for Chagas disease caused by the protozoan parasite Trypanos

119 goal of delivering a new drug candidate for Chagas disease are reported.

120 istry efforts to develop drug candidates for Chagas' disease.

121 te than benznidazole, the drug of choice for Chagas disease treatment, the ant alkaloids presented a

122 Benznidazole is the drug of choice for Chagas disease.

123 d be a novel target for drug development for Chagas cardiomyopathy.

124 e to another, and present case estimates for Chagas disease came from various sources, including WHO

125 The US-based Center of Excellence for Chagas Disease performed an observational study on the s

126 Current therapeutic options for Chagas' disease are limited to benznidazole and nifurtim

127 d women, 1,271 (21.8%) screened positive for Chagas disease.

128 sialidase (TcTS) is a key target protein for Chagas disease chemotherapy.

129 ruzi replication, a parasite responsible for Chagas disease.

130 several vertebrate hosts is responsible for Chagas' disease in Latin America.

131 Pregnant women were screened for Chagas disease by rapid test and received confirmatory s

132 INTERPRETATION: Screening for Chagas disease in asymptomatic Latin American adults liv

133 osoma cruzi, is an important drug target for Chagas disease.

134 Identifying novel therapeutic targets for Chagas disease is a scientific priority.

135 hanisms and identify therapeutic targets for Chagas disease.

136 with at least three different techniques for Chagas disease, maintained at controlled low temperature

137 The current treatment for Chagas disease is not satisfactory, and there is a need

138 bolomic data to develop novel treatments for Chagas disease.

139 o capture the TcVac2-induced protection from Chagas disease.

140 Only a minority of samples from Chagas disease patients possessed antibodies against rLb

141 were uninfected control patients and 120 had Chagas disease (1 group had asymptomatic disease, and 2

142 icular (human African trypanosomiasis (HAT), Chagas disease, cutaneous leishmaniasis, and malaria) ha

143 r, 300 000 individuals are estimated to have Chagas disease in the United States.

144 f the 120 seropositives classified as having Chagas cardiomyopathy, only 31 (26%) presented with ejec

145 revent the deadly cardiac pathology in human Chagas disease is a desirable and currently unattained g

146 factor to prevent myocardial damage in human Chagas disease.

147 soma cruzi leads to the development of human Chagas' disease, yet the functional contributions of the

148 BIA platform for in situ diagnosis of human (Chagas disease and human brucellosis) and animal (bovine

149 associated with activation of DN T cells in Chagas disease and that CD1d blocking leads to downregul

150 onsible for prominent systemic congestion in Chagas disease.

151 tion have been used to study heart damage in Chagas disease.

152 ver, occurrence of primary RV dysfunction in Chagas disease remains controversial.

153 e associated with microthrombus formation in Chagas' disease and a known activator of iPLA2, increase

154 gest that galectin-3 is strongly involved in Chagas disease, not only in the immune response against

155 olvement of MBL/MASP2-associated pathways in Chagas' disease, it is currently unknown whether MBL pla

156 Even with a reduction in Chagas disease prevalence to 0.05% and with large variat

157 Several biomarkers have been reported in Chagas heart disease (ChHD), but most are nonspecific fo

158 nstrated to induce CD8(+) T cell response in Chagas' disease patients, or bind HLA-A*02:01, but are,

159 actome between miRNAs and their targetome in Chagas heart disease by integrating gene and microRNA ex

160 sue relationship between T. cruzi infection, Chagas disease, and host glucose homeostasis.

161 verall, this work provides new insights into Chagas disease pathogenesis and presents an analytical c

162 The most threatening trypanosomiasis is Chagas disease, affecting up to 12 million people in the

163 investigated include malaria, leishmaniasis, Chagas' disease, roundworm, whipworm, pinworm, Chinese l

164 parasites in murine models of leishmaniasis, Chagas disease, and human African trypanosomiasis.

165 ac pathology in a BALB/c mouse model of live Chagas disease.

166 on, AhR influences the development of murine Chagas disease by modulating ROS production and regulati

167 IC50 at 11.9 and 17.2 muM against neglected Chagas' disease causing Trypanosoma cruzi, respectively.

168 = 72), 30/30 Chagas were positive, 30/30 non-Chagas were negative, and 1/12 Leishmania sp. was positi

169 with Trypanosoma cruzi, the causal agent of Chagas cardiomyopathy, we observed a sudden switch from

170 Trypanosoma cruzi, the causative agent of Chagas disease (CD), contains exclusively Fe-dependent s

171 Trypanosoma cruzi, the parasitic agent of Chagas disease and a public health concern throughout La

172 Trypanosoma cruzi (the etiological agent of Chagas disease) adapting via trade-off among three diffe

173 rypanosoma cruzi is the etiological agent of Chagas disease, a neglected and emerging tropical diseas

174 Trypanosoma cruzi is the causative agent of Chagas disease, and infects 5-8 million people in Latin

175 a cruzi ( T. cruzi ), the causative agent of Chagas disease, and the results of structure-activity in

176 Trypanosoma cruzi, the etiological agent of Chagas disease, as well as other trypanosomatids relevan

177 Trypanosoma cruzi, the causative agent of Chagas disease, contains exclusively iron-dependent supe

178 Trypanosoma cruzi, the agent of Chagas disease, does not seem to control gene expression

179 Trypanosoma cruzi, the causative agent of Chagas disease, encodes for an alpha-carbonic anhydrase

180 by Trypanosoma cruzi, the causative agent of Chagas disease, has recently been described, with differ

181 of Trypanosoma cruzi, the etiologic agent of Chagas disease, have been highly inefficient, and no end

182 ected Trypanosoma cruzi, the causal agent of Chagas disease, implying the existence of evasion or tol

183 Trypanosoma cruzi, the etiological agent of Chagas disease, is a protozoan parasite with a complex l

184 infection, which is the etiological agent of Chagas disease, is associated with intense inflammation

185 Trypanosoma cruzi, the causing agent of Chagas disease, leads to an activation of the immune sys

186 at Trypanosoma cruzi, the etiologic agent of Chagas disease, possesses two unique paralogues of the m

187 cellular parasite and the etiologic agent of Chagas disease.

188 Trypanosoma cruzi, the etiological agent of Chagas disease.

189 of Trypanosoma cruzi, the etiologic agent of Chagas disease.

190 te Trypanosoma cruzi, the causative agent of Chagas disease.

191 Trypanosoma cruzi is the etiologic agent of Chagas disease.

192 Trypanosoma cruzi is the causative agent of Chagas disease.

193 an Trypanosoma cruzi, the causative agent of Chagas disease.

194 an Trypanosoma cruzi, the causative agent of Chagas disease.

195 st Trypanosoma cruzi, the causative agent of Chagas disease.

196 e Trypanosoma cruzi, the aetiologic agent of Chagas disease.

197 e: Trypanosoma cruzi, the causative agent of Chagas disease; Trypanosoma brucei, the causative agent

198 in Trypanosoma cruzi, the causative agent of Chagas' disease.

199 an Trypanosoma cruzi, the causative agent of Chagas' disease.

200 tozoan parasites are the causative agents of Chagas disease and sleeping sickness, two neglected trop

201 cruzi parasites are the causative agents of Chagas disease, a leading infectious form of heart failu

202 harmacological interventions in the areas of Chagas' disease and experimental cancer.

203 the clinical and epidemiological aspects of Chagas disease.

204 c_5171 could be used as a novel biomarker of Chagas disease for diagnosis and to assess treatment eff

205 l and regional health and economic burden of Chagas disease from the societal perspective.

206 The economic burden of Chagas disease is similar to or exceeds those of other p

207 ccounts for an estimated 22% of new cases of Chagas disease in Latin America.

208 , there are approximately 8 million cases of Chagas disease in the southern cone of South America alo

209 nts for a growing proportion of new cases of Chagas disease.

210 ic Trypanosoma cruzi infection, the cause of Chagas disease, life-threatening inflammatory diseases d

211 Cardiomyopathy is a serious complication of Chagas' disease, caused by the protozoan parasite Trypan

212 ore attention and efforts towards control of Chagas disease.

213 e findings suggest that during the course of Chagas disease, CD8(+) T cells undergo a gradual loss of

214 ence base to improve laboratory diagnosis of Chagas disease in the United States.

215 disease penetrance and prognostic factors of Chagas cardiomyopathy among asymptomatic Trypanosoma cru

216 atients with indeterminate/digestive form of Chagas disease (35.7%) compared with those with Chagas c

217 ffective therapy against the chronic form of Chagas disease has yet to be discovered and developed.

218 hose with the indeterminate clinical form of Chagas disease, respectively.

219 e indeterminate or cardiac clinical forms of Chagas disease and whether IL-17 expression can be corre

220 f digestive pathologies of clinical forms of Chagas disease.

221 yme, can cure the acute and chronic forms of Chagas disease.

222 se and conclude with a view of the future of Chagas disease diagnosis, pathogenesis, therapy, and pre

223 60, 95% CI: 0.36-0.99) and family history of Chagas disease (aOR: 0.58, 95% CI: 0.34-0.99).

224 Older maternal age, family history of Chagas disease, home conditions, lower education level,

225 eir partnership in the immunopathogenesis of Chagas disease, the chronic infection caused by the intr

226 study examined the prevalence and impact of Chagas cardiomyopathy (CCM) in a US population.

227 There is a substantial annual incidence of Chagas cardiomyopathy among initially asymptomatic T cru

228 in these areas that aid in the management of Chagas disease.

229 iomyocytes, as well as in the mouse model of Chagas disease, supporting the involvement of TcAPx-CcP

230 allow an efficacy study in a mouse model of Chagas disease.

231 ssion of parasite burden in a mouse model of Chagas' disease.

232 Preclinical models of Chagas disease have demonstrated that antigen-specific C

233 cardiologists who adjudicated the outcome of Chagas cardiomyopathy.

234 ypanosoma cruzi is the causative pathogen of Chagas disease and the main culprit for cardiac-related

235 The role of microRNAs in the pathogenesis of Chagas disease has not been well described.

236 nous RvD1 could modulate the pathogenesis of Chagas disease in a murine model.

237 role of autoimmunity in the pathogenesis of Chagas disease remain unanswered, the development of aut

238 rize what is known about the pathogenesis of Chagas heart disease and conclude with a view of the fut

239 parasite persistence and the pathogenesis of Chagas heart disease.

240 t patients diagnosed in the chronic phase of Chagas disease already exhibit heart involvement, and th

241 In vivo tests on the acute phase of Chagas disease gave parasitemia inhibition values twice

242 t in vivo behavior during the acute phase of Chagas disease; and (iii) neither nonspecific toxicity n

243 logy in both the acute and chronic phases of Chagas disease.

244 There is a high prevalence of Chagas disease among Latin American immigrants diagnosed

245 We found a 13% point prevalence of Chagas disease in a sample of New York City immigrants w

246 The pathological progression of Chagas disease is influenced by the infiltration and tra

247 Whether asymptomatic individuals at risk of Chagas disease living in Europe should be screened and t

248 dioprotective role during the acute stage of Chagas' disease.

249 4.4%) patients, 2 of them in early stages of Chagas disease.

250 we evaluated the congenital transmission of Chagas disease (CD) in a nonendemic area.

251 Oral transmission of Chagas disease has emerged in unpredictable situations i

252 Oral transmission of Chagas disease is considered when >1 acute case of febri

253 resents a new candidate for the treatment of Chagas disease.

254 Benznidazole is recommended for treatment of Chagas infection.

255 nd more effective drugs for the treatment of Chagas' disease.

256 ct physiology, but also is a major vector of Chagas disease, an illness that affects approximately se

257 with Rhodnius prolixus, the insect vector of Chagas disease, we show that an ovary dual oxidase (Duox

258 ne bug Rhodnius prolixus is a main vector of Chagas disease, which affects several million people, mo

259 the importance of R. prolixus as vectors of Chagas disease and model organisms in insect physiology,

260 American Trypanosomiasis or Chagas disease is a prevalent, neglected and serious deb

261 linical outcomes of the disease it provokes: Chagas disease (CD).

262 rformed an economic evaluation of systematic Chagas disease screening of the Latin American populatio

263 The Chagas assay exhibited 100% sensitivity (30/30) and spec

264 The Chagas' disease parasite Trypanosoma cruzi elicits a pot

265 o cross-sectional data of infestation by the Chagas disease vector Triatoma infestans in the city of

266 ling the position of major clades (e.g., the Chagas disease vectors Triatominae).

267 The mechanisms underlying resistance of the Chagas disease parasite, Trypanosoma cruzi, to current t

268 Thus, the Chagas assay achieved a combined sensitivity and specifi

269 Approximately 12000 deaths attributable to Chagas disease occur annually due to chronic Chagas dise

270 runcated into fragments that are specific to Chagas disease and have the potential to be used as diag

271 ites in the hearts of those who succumbed to Chagas disease.

272 ted therapeutic options to prevent and treat Chagas disease put 8 million people infected with T. cru

273 gress to viable candidate compounds to treat Chagas disease and human sleeping sickness.

274 s as means of identifying new drugs to treat Chagas disease in the acute phase with greater activity,

275 of only 2 medications available for treating Chagas disease (CD) and currently the only drug availabl

276 liant squaramides as candidates for treating Chagas disease.

277 aetiological agent of the neglected tropical Chagas disease.

278 etiologic agent of American trypanosomiasis (Chagas disease), exhibiting IC(50) values in the nanomol

279 ich in humans cause African trypanosomiasis, Chagas disease, and leishmaniasis, respectively.

280 additional epitope repertoires with unknown Chagas serostatus, assay specificity was 99.8% (998/1000

281 nd mortality in areas of Latin America where Chagas disease is endemic and among infected individuals

282 n the USA (Lyme disease $2.5 billion), where Chagas disease has not been traditionally endemic, sugge

283 costs emanate from the USA and Canada, where Chagas disease has not been traditionally endemic.

284 al diseases (11 with schistosomiasis, 5 with Chagas' disease, and 10 with cutaneous leishmaniasis), a

285 Associations with Chagas cardiomyopathy were tested with multivariate logi

286 (9.3%) had ECG abnormalities consistent with Chagas cardiomyopathy; risk was higher for older women (

287 inical significance, patients diagnosed with Chagas disease, either asymptomatic or with cardiac clin

288 ecies profile is altered in individuals with Chagas disease compared with healthy controls.

289 trol for cardiac autoimmunity, patients with Chagas cardiomyopathy (n=51).

290 ypes, respectively, similar to patients with Chagas cardiomyopathy, compared with 2%, 1%, and 0% in t

291 study RV systolic function in patients with Chagas disease using cardiac magnetic resonance.

292 in toxicity of benznidazole in patients with Chagas disease, determine the serum cytokine profile, an

293 e whole-blood transcriptome of patients with Chagas disease.

294 and CD1d by CD14(+) cells from patients with Chagas disease.

295 worse ventricular function in patients with Chagas disease.

296 antiinflammatory cytokines in patients with Chagas heart disease and those with the indeterminate cl

297 f IFN-gamma by DN T cells from patients with Chagas heart disease, which may be a potential target fo

298 andomized study involving 2854 patients with Chagas' cardiomyopathy who received benznidazole or plac

299 an heart samples obtained from subjects with Chagas disease who underwent heart transplantation showe

300 gas disease (35.7%) compared with those with Chagas cardiomyopathy (36.8%) (P=1.000).